10/23/2018



Marina E. Emborg, M.D. Ph.D.
Professor of Medical Physics
Director, Preclinical Parkinson's Research Program
Wisconsin National Primate Research Center

Transgenic and Chimeric Neuroscience Research:

Exploring the Scientific Opportunities

Afforded by New Nonhuman Primate Models

A Workshop | Washington, DC
October 4, 2018
#NeuroForum



Workshop Planning Committee

Frances Jensen (Chair), University of Pennsylvania, Perelman School of Medicine

Susan Amara, National Institute of Mental Health

Sarah Caddick, THALAMIC

Marina Emborg, Wisconsin National Primate Research Center, University of Wisconsin-Madison

Guoping Feng, Massachusetts Institute of Technology

Joshua Gordon, National Institute of Mental Health

Hank Greely, Stanford University

Jeffrey Kahn, Johns Hopkins University

Walter Koroshetz, National Institute of Neurological Disorders and Stroke

John Morrison, California National Primate Research Center, University of California, Davis

William Newsome, Stanford University

Karen Parker, Stanford University

Michael Steinmetz, National Eye Institute

Andrew Welchman, Wellcome Trust

Stevin Zorn, Mindlmmune Therapeutics, Inc.





Workshop Objectives

To bring together experts and key stakeholders from academia, government, industry, and non-profit organizations to examine the scientific opportunities and challenges, as well as bioethical considerations, of genetically engineered nonhuman primate models for neuroscience research.





What merits genetic modification of NHP?

Identification of unique issues around animal husbandry and care

What kind of infrastructure is required to create reliable/validated models?

related to NHP use, consequences of targeted gene modification

Training next
generation of
scientists to
responsibly conduct
research in this area

National/global regulatory and conduct codes across academia and industry

Central or decentralized? How to enable international collaboration, Data sharing?

Agenda Overview

- Session I: Emerging Transgenic and Chimeric Nonhuman Primate Models for Neuroscience Research and Therapeutic Development for Nervous System Disorders
- Session II: Technology, Research Methodology, and Assessment Tools For Transgenic and Chimeric Nonhuman Primate Models
- Session III: Bioethical Considerations for Transgenic and Chimeric Nonhuman Primate Models in Neuroscience Research
- Session IV: Moving Forward: Policy and Infrastructure Needs to Advance Research





Compared to "traditional" NHP neuroscience research...

...does animal use and care need to be different for "transgenic & chimeric" NHP research?

...does the scientific justification need to be different?

These questions emerge from a genuine concern of Investigators for the animals they work with.

- There is a body of knowledge on how to take care of animals with induced and spontaneous disorders
- There is a system already in place for vetting ideas.
 RFAs, grant peer review and IACUC (between others) put to the test the validity and relevance of the scientific question, the approach and animal care

Paraphrasing Dr. Hyman...

1) Why are we doing NHP research?

- Rodents vs NHPs: modestly social vs. social; olfactory vs. visual; nocturnal vs. diurnal
- NHP models are complimentary to mice models. Translational models introduce scientific constraints. Match model to question.
- Re-education of scientists to avoid limiting model choice by availability

2) Infrastructure and scientific needs:

- We need to learn more about NHP brains
- Building toolkits
- If CRE expression is toxic, what else?
- Specialized nature of facilities, cost, space, requirements generation will benefit from a coordinated but not "soviet state"
- Ensure genetic diversity

3) Ethical issues:

- Beyond benefit/harm issues, NHP justification
- Making sure science is solid
- System should self-regulate
- · Need to communicate: human and animal care teams, scientists with public